Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas

Journal of Pathology

Volumn 181, Issue 2, 1997, Pages 178-182

  Marchetti, Antonio ^a   Buttitta, Fiamma ^a   Pellegrini, Silvia ^a   Bertacca, Gloria ^a   Chella, Antonio ^a   Carnicell, Vittoria ^a   Tognoni, Vittorio ^a   Filardo, Alberto ^a   Angeletti, Carlo Alberto ^a   Bevilacqua, Generoso ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Human; Lung; Metastasis; Neoplasm; P16

Indexed keywords

PROTEIN P16; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING;

ADULT; AGED; BLOTTING, SOUTHERN; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0031025258     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199702)181:2<178::AID-PATH741>3.0.CO;2-5     Document Type: Article

References (28)

1. Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem 1993; 61: 441-470.
2. Hunter T, Pines J. Cyclin and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-582.
3. El-Deiry WS, Tokino T, Valculescu VE, et al. WAF1, a potential mediator of p53 tumour suppression. Cell 1993; 75: 817-825.
4. Polyak K, Lee M-H, Erdijument-Bromage H, Tempst P, Massagué J. Cloning of p27, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59-66.
5. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
6. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994; 371: 257-261.
7. INK4/MTS2-related CDK inhibitor, correlates with wild-type pRB function. Genes Dev 1994; 8: 2939-2952.
8. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995; 9: 639-649.
9. Lukeis R, Irving L, Garson M, Hasthorpe S. Cytogenetics of non-small-cell lung cancer: analysis of consistent non-random abnormalities. Genes, Chromosome Cancer 1990; 2: 116-124.
10. Alopade OI, Buchhagen DL, Malik K, et al. Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res 1993; 53: 2410-2415.
11. Merlo A, Gabrielson E, Askin F, Sidransky D. Frequent loss of chromosome 9 in primary human non-small-cell lung cancer. Cancer Res 1994; 54: 640-642.
12. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in the genesis of many tumour types. Science 1994; 264: 436-440.
13. Nobori T, Muira K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 386: 753-756.
14. Cairns P, Mao L, Merlo A. Rates of p16 (MTS1) mutations in primary tumours with 9p loss. Science 1994; 265: 415-416.
15. INK4 in human cancer. Proc Natl Acad Sci USA 1994; 91: 11045-11049.
16. Ohta M, Nagai H, Shimizu M, et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK41, in melanoma. Cancer Res 1994; 54: 5269-5272.
17. Spruck CH III, Gonzalez-Zulueta M, Shibata A, et al. p16 gene in uncultured tumours. Nature 1994; 370: 183-184.
18. INK4) in human breast carcinomas. Cancer Res 1994; 54: 5262-5264.
19. Zhang S-Y, Klien-Szanto AJP, Sauter ER, et al. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumours of the head and neck. Cancer Res 1994; 54: 5050-5053.
20. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletions mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54: 5547-5551.
21. Hayashi N, Sugimoto J, Tsuchiya E, Ogawa M, Nakamura Y. Somatic mutations of the MTS (multiple tumour suppressor)1/CDK41 (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinoma. Biochem Biophys Res Commun 1994; 202: 1426-1430.
22. Washimi O, Nagatake M, Osada H, et al. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancer. Cancer Res 1995; 55: 514-517.
23. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 1995; 55: 1448-1451.
24. Sato Y, Mukai K, Matsuno Y, et al. The AMeX method: a multipurpose tissue-processing and paraffin-embedding method. Extraction of spooled DNA and its application to Southern blot hybridisation analysis. Am J Pathol 1990; 16: 267-271.
25. World Health Organization. The World Health Organization. Histological typing of lung tumours. Am J Clin Pathol 1982; 77: 123-136.
26. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89: 2255-2335.
27. Marchetti A, Buttitta F, Merlo G, et al. p53 alterations in non-small cell lung cancer correlate with metastatic involvement of hilar and mediastinal lymph-nodes. Cancer Res 1993; 53: 2846-2851.
28. Gruis NA, Weaver-Feldhaus J, Liu Q, et al. Genetic evidence in melanoma and bladder cancer that p16 and p53 function in separate pathways of tumour suppression. Am J Pathol 1995; 146: 1199-1206.